0%
Simulation First Platform

CellOS

CellCo combines computational simulation, generative AI, and medicinal chemistry to engineer glycan-enabled therapeutics with unprecedented precision — turning complex molecular structures into programmable medicines.

Glyco-MDSynthetic DataGenerative EngineGlyco-LLMsSimulationFlywheel
01

Glyco-MD

Massively parallel molecular dynamics and free-energy prediction powered by custom force fields and automated cloud pipelines.

02

Synthetic Data

Order-of-magnitude expansion for scarce-data domains to train robust models.

03

Generative Engine

Training and fine-tuning models for glycans, RNA and complex biomolecular ensembles.

04

Glyco-LLMs

Foundation embeddings for oligosaccharides to assist glyco-therapeutic design.

Benchmark

20x more compounds screened

Our virtual screening pipeline processes orders of magnitude more compounds at the docking/AI stage compared to industry-standard workflows — delivering broader chemical coverage with precise physics-based validation.

Screening Throughput
Step 1: Docking/AI — Compounds screened
Schrödinger (MALT1 Case Study)1,388
CellOS (VS v0)27,000
~20xmore compounds screened vs. industry benchmark
Live Demo

Watch CellOS in action

The Science

The sugar code

Every cell is coated in a dense layer of sugar structures — glycans. They control immune recognition, cell signaling, and pathogen entry, yet remain mostly unknown — and almost entirely unexploited.

~80%
of proteins are glycosylated
<0.1%
structures mapped vs. proteins
10²¹
vast design space
Cell glycocalyx under electron microscopy
Focus Areas

Advancing next-generation therapeutics

We work at the intersection of glycan chemistry, immune biology, and targeted delivery — each area reinforcing the others.

Glycan Programming

Speaking the language of glycans.

The glycan layer controls what enters every cell. We design molecules that speak its language — with atomic precision.

Immune Modulation

Precision immunology starts at the cell surface.

Macrophages, B cells, dendritic cells, neutrophils — each reads glycan signals differently. We exploit that specificity to modulate immune response with programmable precision.

Cell Specificity

Nature's address book.

Glycan ligands direct therapeutics to specific tissues and cell types — RNA, small molecules, antibodies. Leveraging Nature's own playbook.

Targeted RNA Medicines

Every tissue has its own code

Glycan ligands are the molecular addresses that direct therapeutics to specific tissues. We engineer these addresses computationally.

The Immune Arsenal

Cells that defend us

Macrophage

Macrophage

First responder

T Cell

T Cell

Adaptive killer

Natural Killer Cell

Natural Killer Cell

Innate assassin

Neutrophil

Neutrophil

Rapid deployer

Dendritic Cell

Dendritic Cell

Master presenter

Eosinophil

Eosinophil

Parasite hunter

Mast Cell

Mast Cell

Sentinel

Monocyte

Monocyte

Circulating precursor

Blood Cells

Blood Cells

The full ecosystem

High-Throughput Synthesis

CellFlow

CellFlow assembles complex glycan libraries with enzymatic precision at synthetic speed — accessing molecular space that was never programmable before.

Programs

Essential Medicines Initiative

Advancing essential medicines for critical care scenarios where current options are limited, compromised, or don't yet exist.

BIOX-1

Anticoagulant

Biosynthetic Heparin/Enoxaparin

BIOX-2

Tissue Repair

Acute Endothelial & Epithelial Injury

Team

Science-led. Computation-driven.

Previously led biology at
CASPR BiotechAmazon

Leadership

Franco Goytia
Franco Goytia
Chief Executive Officer
Founder/CEO Caspr, COO Amazon Artemis
Carla Gimenez
Carla Gimenez
Chief Scientific Officer
Founder/CSO Caspr, CSO Amazon Artemis
Sofia Valla
Sofia Valla
Chief Program Manager
PhD, Biotechnology, Glycobiology
Anselmo Reggiardo
Anselmo Reggiardo
Chief Product Officer
PhD, Biochemistry
Rodrigo Cossio-Perez
Rodrigo Cossio-Perez
In-Silico Lead
PhD, Computational Biology

Advisors

Michael Jewett
Michael Jewett
Professor of Bioengineering at Stanford University
Francis deSouza
Francis deSouza
Former CEO of Illumina
Matthew DeLisa
Matthew DeLisa
Director, Institute of Biotechnology, Cornell University
Ali Al-Hakim
Ali Al-Hakim
Former FDA Director New Drug Products
Mattheos Koffas
Mattheos Koffas
Professor & Group Leader at RPI
Diego Rey
Diego Rey
Endpoint Health, GeneWEAVE (acq. Roche)
Jim Lalonde
Jim Lalonde
Former SVP R&D at Codexis
Rene Labatut
Rene Labatut
Former VP Manufacturing Tech at Sanofi
Supported by
Draper AssociatesMontage VenturesIndie BioSpaceCadetBoost VCFJ LabsJ&J JLABS
Get In Touch

Connect with us

Stay updated

or
Contact us directly